WebNov 23, 2024 · INCB000928 is a novel and orally available drug that inhibits ALK2 protein activity and has been shown to prevent ossification in a laboratory mouse model of FOP. Patients with end-stage renal disease who undergo hemodialysis may require a different dose of INCB000928. WebNov 5, 2024 · INCB000928 is a potent, orally bioavailable, and highly selective small molecule inhibitor of ALK2, and may represent a potential therapeutic strategy for hepcidin-induced anemia. INCB 00928-104 is designed to evaluate the safety and tolerability of INCB000928 as monotherapy or in combination with ruxolitinib in patients with anemia …
Phase 1/2 Study of INCB000928 As Monotherapy or in …
WebINCB000928 is a novel and orally available drug that inhibits ALK2 protein activity and has been shown to prevent ossification in a laboratory mouse model of FOP. Patients with … WebTo Assess the Effectiveness, Safety, and Tolerability of INCB000928 in Participants With Fibrodysplasia Ossificans Progressiva - Mayo Clinic To Assess the Effectiveness, Safety, and Tolerability of INCB000928 in Participants With Fibrodysplasia Ossificans Progressiva Overview Study type Interventional Study phase 2 Study IDs About this study how to request a dbs check
To Assess the Effectiveness, Safety, and Tolerability of INCB000928 …
WebOct 8, 2024 · This Phase 2, Randomized, Double-Blind, Placebo-Controlled Study is intended to evaluate the Efficacy, Safety, and Tolerability and PK of INCB000928 administered to participants with a clinical diagnosis of fibrodysplasia ossificans progressiva (FOP). WebAnother selective ALK2 inhibitor, INCB000928 that was originally developed to treat anemia as an iron homeostasis modulator, is now being evaluated for the ecacy and tol- erability in the treatment of FOP in the phase II clinical trial (NCT05090891) [51, 52] (Table 1). WebNov 23, 2024 · While the recurrent c.617G>A; p.R206H mutation was found in all cases of classic FOP and most cases of FOP-plus, novel ACVR1 mutations occur in the FOP variants and two cases of FOP-plus. north carolina at syracuse